Knowledge, experiences, and attitudes of Australian General Practitioners towards medicinal cannabis: a 2021–2022 survey

Abstract

Background

The Australian Federal Government legalised medicinal cannabis (MC) in November 2016 [1, 2]. This has enabled patients to be prescribed a wide range of products containing Δ⁹-tetrahydrocannabinol (THC) and/or cannabidiol (CBD) [3, 4]. These products are mostly classified as ‘unregistered medicines’ by the Australian drug regulator (the Therapeutic Goods Administration, TGA) and doctors must apply for approval to prescribe such products through the Special Access Schemes (SAS-A or SAS-B) or the Authorised Prescriber (AP) Scheme [2, 3, 5]. The SAS schemes allows doctors to seek approval from the TGA to prescribe MC products to an individual patient, while the AP scheme provides permission to prescribe a MC product to multiple patients suffering from the same condition [6]. Both schemes place the onus of assessing clinical need, justifying MC prescribing, and choosing an appropriate MC product on the prescribing clinician. The subsequent prescription is then dispensed through a pharmacy [2]. The first few years of MC access were characterised by small prescription numbers amidst criticisms that the schemes were too complex, lengthy and restrictive, and products, too expensive [5, 7–9]. The last two years, however, has seen a substantial increase in prescriptions with more than 320,000 SAS-B approvals involving more than 100,000 patients and 4,600 prescribers granted at the time of writing (December 2022) [5, 10, 11].

General practitioners (GPs) are at the forefront of MC prescribing in Australia [12] and handle many patient enquiries [3, 7]. Understanding the experiences of GPs around MC in clinical practice is, therefore, of major interest. Our research team previously surveyed Australian GPs (n = 640) on their knowledge and attitudes towards MC in 2017, approximately one year following legalisation [7]. Results showed that most GPs were cautiously supportive of MC therapy but often felt ‘uncomfortable’ handling MC enquiries and felt poorly educated in the area. Similar outcomes have emerged from other surveys of medical practitioners in other countries [13–17].

Since our original survey, the prescribing landscape has changed considerably in Australia. The number of prescribing doctors has increased considerably and prescribing processes have been streamlined by the drug regulator and government [4]. To better understand how these developments have impacted GPs, we have conducted a new and updated survey of Australian GPs. Many of the original questions were retained, allowing us to investigate how attitudes, perceived knowledge, and concerns of GPs may have changed over time.

Method

Results

A total of 617 GPs initiated the survey. Those who failed to complete all six sections (n = 112) were removed from the analysis leaving a total of 505 participants. As the true number of GPs exposed to the advertisement of the educational event and survey through the Healthed website and email-base is unknown, the survey response rate could not be reliably calculated.

Discussion

This study explored the current knowledge, experiences, and attitudes of Australian GPs towards MC, and provides key insights into this emerging field subsequent to our original survey of five years ago [7]. This survey is reasonably comprehensive, with 42-items scoping numerous aspects of MC that are relevant and specific to general practice. Overall, most GPs had received MC enquiries from patients. Yet only a minority felt comfortable managing these enquiries. Only around 21% of the cohort were MC ‘prescribers’, around the same proportion (22%) of the overall cohort reporting adequate self-perceived knowledge around MC in clinical practice. Indeed, many GPs felt they had inadequate knowledge of MC products, MC access pathways and optimal clinical practice. A need for further education in this area was also endorsed in the open-ended comments.

A disproportionate number of MC prescribers resided in Queensland, in agreement with recent government data on prescriber location for SAS-B approvals [5]. Overall, however, GP demographics in the current survey were strikingly similar to our original 2017 survey [7]. More GPs had received recent MC enquiries than in our original survey (85.3% vs. 61.5% respectively in past three months). This observation is consistent with the recent and considerable rise in MC prescribing [2, 10] likely driven by recent initiatives aimed at improving access pathways, as well as the growing acceptance of MC from health professionals [10, 20, 21]. The mental health burden of the COVID-19 pandemic has also been suggested as a contributing factor for the demand for MC products over the past two years [10].

Interestingly, however, GP comfort levels with managing MC enquiries remain low and unchanged since the original survey despite the increase in patient enquiries. Low comfort levels around managing and prescribing cannabis-based therapy are in line with other surveys of physicians [13–17]. Australian GPs currently select from > 240 distinct MC products to treat more than 120 distinct medical conditions and often prescribe in the absence of high-quality supporting evidence of efficacy [3, 21, 22]. The specialised prescribing process and costly nature of MC products may also present hurdles in GP discussions with patients [7, 9, 23]. Most GP participants endorsed these two issues as ongoing problems. Formal education around MC has been suggested to improved comfort levels [14, 15, 24].

The greatest support for the use of MC was in terminal and/or often difficult-to-treat medical conditions such as palliative care, chronic cancer pain and CINV, more so than our original survey (Supplementary Table S4) [7] and similar to other international studies [25–27]. MC is often seen as a therapy of last resort, where conventional treatment options have been exhausted [10, 15, 25, 27, 28]. Furthermore, the evidence around the use of cannabis-based medicine in these indications has been well-reviewed and summarised in a variety of comprehensive guidance documents by organisations such as the TGA [2, 3, 21].

The extent of participating GPs support for the use of MC in anxiety, depression and insomnia was not well-endorsed relative to other indications, perhaps reflecting the limited evidence for MC efficacy in these conditions [29, 30]. Additional factors here may be the availability of relatively safe and effective conventional therapies for these conditions, as well as concerns around the impact of THC use on mental health [16, 27, 31]. When compared to the original survey however, participating GPs demonstrated increased support for the use of MC in most health conditions compared to the original survey (Supplementary Table 4) [7] and this included mental health conditions such as anxiety and PTSD as well as insomnia and chronic pain. This agrees with TGA data showing chronic pain, anxiety and sleep disturbance as the leading indications for SAS-B approvals [5].

Participating GPs who were MC prescribers had prescribed MC most often for chronic pain and anxiety (Supplementary Table 2). However, prescribing for these indications is supported by relatively sparse evidence [32–35]. Indeed, participating GPs were clearly aware of the limited evidence for clinical efficacy of MC, as has been noted in previous surveys [13, 16, 17, 31]. Widespread prescribing of MC in the absence of evidence suggests a patient-driven rather GP-driven process, or possibly that clinical efficacy is readily apparent to GPs but has yet to be properly captured by published clinical trials.

Concerns endorsed by GPs around THC included driving impairment, addiction and dependence; and are legitimate given current evidence [22, 36]. Some GPs expressed concern around THC causing weight gain; however, regular cannabis users tend to have a leaner phenotype than non-users [37, 38]. Legitimate concerns were expressed around drug-drug interactions with CBD [22]. However, concerns expressed around CBD causing driving and cognitive impairment are unfounded [39, 40]. Similarly, concerns existed around addiction and psychosis, yet CBD has shown some promise as a treatment for these conditions [41, 42]. Concerns around MC are therefore not always based on the most current evidence. The lack of endorsement for availability of low dose CBD products in pharmacies may reflect misconceptions around the safety of such products by GPs.

Despite safety concerns, few GPs believed the risk of side effects were “too high” (15.6% in the current survey vs. 19.8% in the original survey). Notably, GPs rated prescription opioids, benzodiazepines, and chemotherapy drugs as more hazardous than MC products, to a greater extent than the original survey [7]. This indicates increasing acknowledgement of the safety of cannabis-based medicines as clinical experience with MC grows.

The low perceived knowledge of GPs around MC, particularly amongst non-prescribers, is perhaps the most striking outcome of the survey and was reiterated in open-ended comments. Notably, most GPs (79%) endorsed the need for compulsory, MC-specific training for prescribers, a belief that has been maintained since the original survey (78.6%). Low knowledge has been highlighted repeatedly in previous surveys of physician around MC [13, 15–17, 26]. It is essential that GPs are supported in developing a sound knowledge around MC, regardless of whether they prescribe MC products or not. Professional organisations will play a leading role in educational initiatives in this area. Knowledge drives optimal patient care [7], and lack thereof may contribute to inadequate provision of support including missed or delayed treatment opportunities [43]. This should be a priority given the ongoing surge in demand for MC therapy.

There are around 4600 MC prescribers in Australia [5] of whom approximately 80% are thought to be GPs (i.e., around 3680) [12]. With a total of 31,000 GPs in Australia [44] MC prescribers were perhaps over-represented in our cohort (21%; 110/505) compared to the overall GP population (12%, 3680/31,000). The 505 GPs included in this study is only a small proportion of the total Australian population of ~ 31,000 GPs [45] such that issues of sample representativeness are worthy of consideration. Government data show Australian GPs to be 41.0% identifying as female, 40.0% aged ≥ 55 years and 32.1% located in NSW [45] compared to 59.8% identifying as female, 51.7% aged ≥ 55 years and 33.5% located in NSW respectively in the current study. Other limitations include recruitment being limited to GPs participating in continuing education and use of an on-line recruitment strategy due to the COVID-19 pandemic that may have biased the cohort towards more technologically adept GPs.

Conclusion

There is accelerating demand for MC products in Australia, in line with global trends [23]. GPs are well positioned to assist in the safe and efficacious use of cannabis-based medicines in the community. Training around MC is required to address the long-standing concerns of GPs around knowledge and confidence in this area. Findings from this study can be used to develop educational initiatives and promote best practice. Australia has the potential to act as exemplar for other countries in guiding high quality MC prescribing and product utilisation in a government-regulated model. Many countries, such as the United Kingdom, face similar access challenges as those of Australia but are yet to utilise GPs as independent MC prescribers, limiting MC prescribing approvals to specialists only [46, 47].

Supplementary Information

Acknowledgements

Abbreviations

Authors’ contributions

Zeeta Bawa, Danielle McCartney, Ramesh Manocha and Iain S. McGregor contributed to the conception and design of the research project and/or output. Zeeta Bawa was involved in data acquisition; Zeeta Bawa, Danielle McCartney and Iain S. McGregor contributed to the analysis and interpretation of the research data; and authors all were involved in drafting and critically revising the manuscript and approved the final submitted version.

Funding

This work was supported by The Lambert Initiative for Cannabinoid Therapeutics, a philanthropically funded centre for medicinal cannabis research at The University of Sydney.

Availability of data and materials

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Footnotes

References